Business Context and Reporting Period
Company: Bausch Health Companies Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2026
Business Overview: A global specialty pharmaceutical and medical device company operating in gastroenterology, hepatology, neuroscience, dermatology, and eye health (via ~87% ownership of Bausch + Lomb). The company is actively managing a planned separation of its Bausch + Lomb eye health business.
Key Financial Metrics
| Metric (in millions) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Revenues | $2,852 | $5,376 |
| Operating Income (Loss) | $740 | $(210) |
| Net Income (Loss) Attributable to BHC | $258 | $(1,165) |
| Diluted EPS | $0.68 | $(3.12) |
| Operating Cash Flow (6mo) | $900 | |
| Total Debt (Principal) | $20,239 | |
| Cash & Equivalents | $1,825 |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 13% ($322M) for the quarter and 12% ($587M) for the six months compared to the prior year periods. Growth was driven by improved net realized pricing, favorable foreign currency impacts, and acquisitions, partially offset by lower volumes and channel exits.
- Goodwill Impairment: A significant non-cash goodwill impairment charge of $1,426 million was recorded in the first half of 2026 related to the Salix reporting unit. This followed the failure of two Phase 3 clinical trials for a rifaximin soluble solid dispersion formulation in January 2026.
- Profitability: While the quarter ended June 30, 2026, was profitable with $740M operating income, the six-month period resulted in an operating loss of $210M, primarily due to the goodwill impairment. This contrasts with an operating income of $720M for the six months ended June 30, 2025.
- Segment Performance:
- Salix: Revenue up 21% (Q3) and 20% (6mo); Profit up 33% (Q3) and 30% (6mo).
- Solta Medical: Revenue up 38% (Q3) and 44% (6mo), driven by the Shibo Zhenmei acquisition.
- Bausch + Lomb: Revenue up 9% (Q3) and 9% (6mo); Profit up 35% (Q3) and 43% (6mo).
Guidance, Outlook, Risks, and Unusual Items
- Capital Structure Management: The company executed significant refinancing in 2025 and early 2026, including the April 2025 Refinancing Transactions and B+L refinancing activities, extending debt maturities and reducing short-term cash requirements.
- B+L Separation: The company continues to evaluate the separation of its Bausch + Lomb business. Completion is subject to achieving targeted debt leverage ratios and shareholder approvals. Cash held by B+L entities is generally not available to Bausch Health unless paid as a dividend.
- Legal Proceedings:
- Xifaxan Litigation: Ongoing Paragraph IV proceedings against generic manufacturers. The FDA remains enjoined from approving the first generic ANDA until October 2029 based on recent court rulings.
- Antitrust: Pending multidistrict antitrust litigation regarding generic pricing; a Canadian antitrust action was dismissed in February 2026.
- Product Liability: Pending Shower to Shower talc litigation, though the company expects indemnification from Johnson & Johnson.
- Regulatory & Pricing Risks:
- Inflation Reduction Act (IRA): Xifaxan was selected for Medicare price negotiation. The negotiated price becomes effective January 1, 2027, expected to reduce revenue and cash flows.
- Tariffs: The company is evaluating the impact of new U.S. tariffs on pharmaceuticals, though it does not currently expect a material impact.
- Unusual Items: The $1,426M goodwill impairment is a non-recurring, non-cash charge. Additionally, the company recorded $16M in acquired IPR&D costs and $9M in asset impairments during the six-month period.
Investor Verification Checklist
- Goodwill Impairment Impact: Verify the long-term implications of the failed Phase 3 trials on the Salix segment's future cash flow projections and remaining goodwill balance ($1,733M).
- Debt Maturities: Review the debt maturity schedule, noting $29M due in the remainder of 2026 and significant maturities in 2028 ($3,766M) and 2030 ($4,173M).
- Xifaxan Pricing: Assess the financial modeling for the 2027 IRA price negotiation impact on the company's primary revenue driver (Xifaxan represents ~85% of Salix revenue).
- B+L Separation Timeline: Monitor progress on debt leverage ratios required to finalize the Bausch + Lomb spin-off and the potential for dividend distributions from B+L.
- Litigation Exposure: Track the status of the Xifaxan generic litigation and the outcome of the appeal regarding the Kelk securities litigation (oral argument scheduled for September 2026).